Vertex SVP Ambrose sells 1,376 shares in plan

Vertex Pharmaceuticals executive Kristen Ambrose reported insider share sales and tax-related share withholding.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Kristen Ambrose reported insider share sales and tax-related share withholding. On February 11, 2026, she completed an open-market sale of 1,376 shares of common stock at $460.43 per share. On February 10, 2026, 592 shares were disposed of at $468.41 per share to cover tax or exercise-related obligations.

Following these transactions, Ambrose directly owned 10,127 shares of Vertex common stock. The sales were made under a company-approved Rule 10b5-1 trading plan that was entered into on August 8, 2025, indicating the trades were pre-arranged rather than discretionary decisions at the time of sale.

Insider Trade Summary

Net Seller: 1,376 shares

Net Sell 2 txns

Insider Ambrose Kristen

Role SVP & Chief Accounting Officer

Sold 1,376 shs ($634K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,376	$460.43	$634K
Exercise Price or Tax Liability	Common Stock	592	$468.41	$277K

Holdings After Transaction: Common Stock — 10,127 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Kristen Ambrose report at Vertex (VRTX)?

Kristen Ambrose, SVP & Chief Accounting Officer, reported selling 1,376 shares of Vertex common stock and disposing of 592 shares to satisfy obligations. These transactions left her with 10,127 directly owned shares according to the reported Form 4 filing details.

At what prices did Kristen Ambrose trade Vertex (VRTX) shares?

Kristen Ambrose’s Form 4 shows a sale of 1,376 Vertex shares at $460.43 per share and a separate tax-withholding disposal of 592 shares at $468.41 per share. Both transactions involved common stock and were reported as direct ownership changes.

How many Vertex (VRTX) shares does Kristen Ambrose own after the Form 4 transactions?

After the reported transactions, Kristen Ambrose directly owns 10,127 shares of Vertex common stock. This figure reflects her holdings following both the 1,376-share open-market sale and the 592-share tax-withholding disposition disclosed in the Form 4.

Was Kristen Ambrose’s sale of Vertex (VRTX) shares under a 10b5-1 plan?

Yes. The Form 4 footnote states the transaction was made under a company-approved Rule 10b5-1 trading plan entered on August 8, 2025. Such plans pre-schedule trades, aiming to separate them from short-term market or personal timing decisions.

What roles does Kristen Ambrose hold at Vertex (VRTX)?

Kristen Ambrose is identified in the Form 4 as an officer of Vertex Pharmaceuticals, serving as Senior Vice President and Chief Accounting Officer. The filing confirms she is not listed as a director or a 10% beneficial owner of the company.

What types of transactions are reported in Kristen Ambrose’s Vertex (VRTX) Form 4?

The Form 4 reports two non-derivative transactions: an open-market sale coded “S” for 1,376 common shares and a tax-withholding disposition coded “F” for 592 common shares. Both transactions involved directly held stock rather than indirect or derivative interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:47 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ambrose Kristen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		F		592	D	$468.41	11,503	D
Common Stock	02/11/2026		S(1)		1,376	D	$460.43	10,127	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.